<ul><li class="bwlistitemmarginbottom"><i><b>Net Sales Increase 13% to $50.1 Million</b></i></li><li class="bwlistitemmarginbottom"><i><b>Net Income of $2.1 Million, or $0.09 EPS vs. $0.09 EPS in Q1FY09</b></i></li><li class="bwlistitemmarginbottom"><i><b>Conference Call Begins Today at 4:30 p.m. Eastern Time</b></i></li></ul><br />

AngioDynamics Introduces DuraMax™ Chronic Dialysis Catheter at 2009 CIRSE Scientific Meeting QUEENSBURY, N.Y. September 23, 2009 — AngioDynamics (NASDAQ: ANGO) has introduced the DuraMax™ stepped chronic dialysis catheter at the 2009 Cardiovascular and Interventional Radiological

AngioDynamics to Hold Fiscal 2010 First Quarter Financial Results Conference Call on October 6, 2009 QUEENSBURY, N.Y. --(BUSINESS WIRE)--Sep. 21, 2009-- AngioDynamics (NASDAQ:ANGO) , a leading provider of innovative medical devices used by interventional radiologists and surgeons for the

AngioDynamics to Participate in the Canaccord Adams 29th Annual Growth Stock Conference QUEENSBURY, N.Y. --(BUSINESS WIRE)--Aug. 4, 2009-- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease,

AngioDynamics Appoints Shawn McCarthy Senior Vice President and General Manager of Its Peripheral Vascular Business Unit QUEENSBURY, N.Y., Jul 21, 2009 (BUSINESS WIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of

Fourth Quarter Net Sales Increase 13% to $52.8 Million Fourth Quarter Net Income of $2.9 Million, or $0.12 EPS vs $0.02 EPS a Year Ago Fourth Quarter EPS of $0.14 Prior to Non-Recurring Costs, vs $0.19 a Year Ago Prior to Litigation Costs, Reflecting Investments in IRE Technology and Sales and Marketing Fourth Quarter Non GAAP EBITDA of $0.32 Per Share vs $0.12 Per Share a Year Ago Company Conference Call Begins Today at 4:30 p.m. Eastern Time

Angiodynamics Offers New, High Flexibility Rfa Device For Cancer Tumor Ablation QUEENSBURY, N.Y. July 2, 2009 – The new StarBurst® XLi-Enhanced Semi-Flex probe from AngioDynamics (NASDAQ: ANGO) is the first radiofrequency ablation (RFA) device specifically designed to deliver a 7cm

AngioDynamics to Hold Fiscal 2009 Fourth Quarter and Full Year Financial Results Conference Call on July 16, 2009 QUEENSBURY, N.Y. --(BUSINESS WIRE)--Jul. 2, 2009-- AngioDynamics, Inc. (NASDAQ:ANGO) , a leading provider of innovative medical devices used by interventional radiologists and surgeons

AngioDynamics to Participate in the Eighth Annual JMP Securities Research Conference QUEENSBURY, N.Y. --(BUSINESS WIRE)--May. 14, 2009-- AngioDynamics (NASDAQ:ANGO) , a leading provider of innovative medical devices used by interventional radiologists and surgeons for the minimally-invasive

Jan Keltjens Appointed to Board of Directors of AngioDynamics QUEENSBURY, N.Y. --(BUSINESS WIRE)--May. 11, 2009-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists and surgeons for the minimally-invasive treatment of cancer and

AngioDynamics to Participate in the Bank of America and Merrill Lynch 2009 Health Care Conference QUEENSBURY, N.Y., May 07, 2009 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists and surgeons for the

Results include fewer complications in patients treated with AngioDynamics device

AngioDynamics Reports Financial Results for Fiscal 2009 Third Quarter Net Sales Increase 21% to $49.4 Million Net Income of $1.9 Million and EPS of $0.08; EPS of $0.15 Prior to Expense Associated with Completion of CEO Transition (Non GAAP) EBITDA of $5.7 Million or $0.23 Per Share Conference Call

AngioDynamics to Report Fiscal Third Quarter 2009 Financial Results and Hold Conference Call on April 2, 2009 QUEENSBURY, N.Y. --(BUSINESS WIRE)--Mar. 24, 2009-- AngioDynamics, Inc. (NASDAQ:ANGO) , a leading provider of innovative medical devices used by interventional radiologists, nephrologists

Jan Keltjens Appointed President & CEO of AngioDynamics Executive Brings More Than 20 Years of Successful Medical Industry Leadership Experience to the Company QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Jan. 21, 2009 -- AngioDynamics, Inc. (NASDAQ:ANGO) announced its Board of Directors has appointed Jan

AngioDynamics to Sponsor Symposium on First Human Clinical Experience with IRE Technology QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Jan. 16, 2009 -- AngioDynamics Inc. (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the

Benephit Only FDA-Cleared Device to Address Acute Kidney Injury Market

AngioDynamics to Participate in the 27th Annual J.P. Morgan Healthcare Conference QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Jan. 9, 2009 -- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally

AngioDynamics Reports Financial Results for Fiscal 2009 Second Quarter Net Sales Increase 17% to $48.5 Million Net Income of $2.9 Million and EPS of $0.12 (Non GAAP) EBITDA of $7.8 Million or $0.32 Per Share First IRE NanoKnife™ Sales Recorded Conference Call Begins Today at 4:30 p.m.

NanoKnife(TM) System Used to Perform Cases<br>
Previous Cases at The Alfred Continue to Show Success